Shares of ICU Medical Inc. (NASDAQ:ICUI) traded down 1.3% during mid-day trading on Monday . The company traded as low as $108.51 and last traded at $111.22, with a volume of 59,633 shares traded. The stock had previously closed at $112.74.

A number of analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Piper Jaffray Cos. restated a “neutral” rating and set a $110.00 price objective on shares of ICU Medical in a report on Saturday, April 23rd.

The firm has a 50-day moving average of $108.79 and a 200-day moving average of $100.93. The firm has a market capitalization of $1.79 billion and a PE ratio of 36.11.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Tuesday, May 10th. The company reported $1.14 EPS for the quarter, beating the Zacks’ consensus estimate of $1.01 by $0.13. The business had revenue of $89.90 million for the quarter, compared to the consensus estimate of $88.04 million. During the same quarter last year, the firm posted $0.60 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Analysts expect that ICU Medical Inc. will post $4.43 EPS for the current fiscal year.

In other news, Director Robert S. Swinney sold 1,875 shares of the business’s stock in a transaction on Monday, May 9th. The shares were sold at an average price of $101.40, for a total transaction of $190,125.00. Following the sale, the director now owns 19,633 shares in the company, valued at approximately $1,990,786.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Steven Riggs sold 20,000 shares of the business’s stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $110.00, for a total transaction of $2,200,000.00. Following the sale, the vice president now owns 21,378 shares in the company, valued at approximately $2,351,580. The disclosure for this sale can be found here.

Other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers boosted its position in shares of ICU Medical by 4.8% in the fourth quarter. Rhumbline Advisers now owns 19,584 shares of the company’s stock worth $2,209,000 after buying an additional 892 shares during the last quarter. Russell Frank Co boosted its position in ICU Medical by 17.7% in the fourth quarter. Russell Frank Co now owns 34,076 shares of the company’s stock valued at $3,836,000 after buying an additional 5,117 shares in the last quarter. Eagle Asset Management boosted its position in ICU Medical by 94.5% in the third quarter. Eagle Asset Management now owns 420,854 shares of the company’s stock valued at $46,082,000 after buying an additional 204,469 shares in the last quarter. Nationwide Fund Advisors boosted its position in ICU Medical by 13.5% in the fourth quarter. Nationwide Fund Advisors now owns 36,714 shares of the company’s stock valued at $4,141,000 after buying an additional 4,381 shares in the last quarter. Finally, Sei Investments Co. boosted its position in ICU Medical by 38.1% in the fourth quarter. Sei Investments Co. now owns 9,629 shares of the company’s stock valued at $1,086,000 after buying an additional 2,657 shares in the last quarter.

ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and innovative hemodynamic monitoring systems.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.